Cytrx Corp (NASDAQ:CYTR)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.

Recs

0
Player Avatar willphipps (43.57) Submitted: 12/3/2007 5:24:39 PM : Outperform Start Price: $21.23 CYTR Score: -78.12

A buy at $3.30 or less...

Featured Broker Partners


Advertisement